Cervical cancer is a pressing global health crisis, claiming approximately 340,000 lives each year. This disease disproportionately affects women in lower-income countries, where they are three times more likely to develop cervical cancer and six times more likely to die from it compared to their counterparts in wealthier nations. The urgency to increase HPV vaccination coverage is paramount to combat this preventable disease.
The HPV vaccine is typically administered during adolescence, a time when routine pediatric visits decline. This gap in healthcare access can lead to lower vaccination rates, which is concerning given that the World Health Organization (WHO) has set ambitious targets for 2030. These include ensuring that 90% of girls are vaccinated against HPV by age 15, as part of the 90-70-90 strategy aimed at eliminating cervical cancer.
Recent studies conducted by PATH in collaboration with immunization program managers have shed light on the operational context and costs associated with HPV vaccine delivery. The research focused on six countries: Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda, providing critical insights into effective vaccination strategies. Notably, Rwanda has achieved an impressive vaccination coverage rate of nearly 98%, setting a benchmark for other nations.
Despite the progress, the statistics remain alarming. Cervical cancer is the fourth most common cancer among women globally, with around 600,000 new cases diagnosed each year. Furthermore, more than 90% of cervical cancer deaths occur in low- and middle-income countries, highlighting the urgent need for equitable healthcare solutions.
Health advocates emphasize that cervical cancer should no longer be a cause of death for women. “Cervical cancer elimination must become a financing priority,” one expert stated, underscoring the need for increased funding and resources to support vaccination efforts. The tragic reality is not only the scale of the disease but also the stark inequalities that persist in healthcare access.
The WHO’s 90-70-90 targets also include ensuring that 90% of women are screened for cervical disease by age 35 and again by age 45, as well as treating 90% of women diagnosed with cervical disease. Achieving these milestones is critical to reducing the burden of cervical cancer and improving health outcomes for women worldwide.
The first World Cervical Cancer Elimination Day was marked in November 2025, signaling a global commitment to eradicate this disease. If successful, it would represent a historic achievement in public health, marking the first time humanity has eliminated a cancer as a public health threat.
As the window for action remains open, the tools for combating cervical cancer are available. However, the path forward requires concerted efforts from governments, health organizations, and communities to prioritize HPV vaccination and address the inequalities that fuel this health crisis. Details remain unconfirmed regarding the full impact of these initiatives, but the stakes could not be higher for women’s health globally.
